More recently, combination therapy of BRAF and MEK inhibitors has improved response rates to approximately 70% in patients with BRAFV600E mutant melanoma while exhibiting evidence of clinical benefit in almost all patients [6]. This evidence concerns the gene BRAF and melanoma.